2024
Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP)
Hooshyari Z, Mohammadi M, Salmanian M, Ahmadi N, Khaleghi A, Garakani A. Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP). European Child & Adolescent Psychiatry 2024, 33: 3965-3978. PMID: 38656607, DOI: 10.1007/s00787-024-02441-7.Peer-Reviewed Original ResearchPrevalence of post-traumatic stress disorderPost-traumatic stress disorderTraumatic eventsAnxiety disordersStress disorderPsychiatric disordersSchool-Age Children-Present and Lifetime VersionKiddie Schedule for Affective DisordersSchedule for Affective DisordersLifetime prevalenceLifetime prevalence of post-traumatic stress disorderType of traumatic eventPredictors of post-traumatic stress disorderRates of PTSDSeparation anxiety disorderGeneralized anxiety disorderK-SADS-PLOppositional defiant disorderPrevalence of PTSDRates of comorbidityAdolescent psychiatric disordersLifetime prevalence ratesPrevalence rates of comorbiditiesDepressive disorderLifetime Version
2021
Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?
Thom RP, Alexander JL, Baron D, Garakani A, Gross L, Pine JH, Radhakrishnan R, Slaby A, Sumner CR. Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough? Journal Of Psychiatric Practice 2021, 27: 361-371. PMID: 34529602, DOI: 10.1097/pra.0000000000000578.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsLong-term SSRI useSSRI useEase of titrationFirst-line medicationSerotonin reuptake inhibitorsRisk-benefit ratioMajor depressive disorderGeneral health risksShort-term useClinical practice considerationsDiscontinuation syndromeReuptake inhibitorsSafety profileDepressive disorderPatientsPsychiatric conditionsRelapse preventionMedicationsPossible adverse consequencesSpecial populationsAnxiety disordersTolerabilityPrescribersAdverse consequences
2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetine